Why the study?
Energetic deficiency of cardiomyocytes causes heart failure, and it was hypothesized that trimetazidine protects cardiomyocytes from pressure overload-induced heart failure by improving myocardial metabolism.
Does trimetazidine improve left ventricular function and myocardial metabolism in pressure overload-induced heart failure models?
Does trimetazidine improve left ventricular function and myocardial metabolism in pressure overload-induced heart failure models?
Trimetazidine protects against pressure overload-induced heart failure by improving myocardial mitochondrial function and glucose uptake via AMPK activation in preclinical models.
Answers are grounded in this paper and cite their sources.
Supports trimetazidine via AMPK in TAC models; leaves open clinical translation in human pressure-overload HF.
Energic deficiency of cardiomyocytes is a dominant cause of heart failure. An antianginal agent, trimetazidine improves the myocardial energetic supply. We presumed that trimetazidine protects the cardiomyocytes from the pressure overload-induced heart failure through improving the myocardial metabolism. C57BL/6 mice were subjected to transverse aortic constriction (TAC). After 4 weeks of TAC, heart failure was observed in mice manifested by an increased left ventricular (LV) chamber dimension, an impaired LV ejection fraction evaluated by echocardiography analysis, which were significantly restrained by the treatment of trimetazidine. Trimetazidine restored the mitochondrial morphology and function tested by cardiac transmission electron microscope and mitochondrial dynamic proteins analysis. Positron emission tomography showed that trimetazidine significantly elevated the glucose uptake in TAC mouse heart. Trimetazidine restrained the impairments of the insulin signaling in TAC mice and promoted the translocation of glucose transporter type IV (GLUT4) from the storage vesicle to membrane. However, these cardioprotective effects of trimetazidine in TAC mice were notably abolished by compound C (C.C), a specific AMPK inhibitor. The enlargement of neonatal rat cardiomyocyte induced by mechanical stretch, together with the increased expression of hypertrophy-associated proteins, mitochondria deformation and dysfunction were significantly ameliorated by trimetazidine. Trimetazidine enhanced the isolated cardiomyocyte glucose uptake in vitro . These benefits brought by trimetazidine were also removed with the presence of C.C. In conclusion, trimetazidine attenuated pressure overload-induced heart failure through improving myocardial mitochondrial function and glucose uptake via AMPK.
No takes yet. Share an insight, caveat, or question.
Shu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: